Clinicians face a difficulty in managing interstitial lung illness caused by connective tissue disease since it is a diverse collection of diseases with no clear standards to follow and only a few randomised controlled studies to guide therapy. Several medicines have been tried to treat interstitial lung disease caused by connective tissue disease, with primarily retrospective studies or small case series demonstrating effectiveness. Finally, the medicine, dose, and length of therapy should be tailored to each patient after evaluating the risks of adverse pharmacological effects against the risk of disease progression.
This study profiles several immunosuppressive regimens, concentrating on the available data on the efficacy of each medicine, probable side effects, and suggested drug monitoring.
